Antifibrotická terapie a její indikace u intersticiální plicní fibrózy
| Autoři | |
|---|---|
| Rok publikování | 2022 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Vnitřní lékařství |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.casopisvnitrnilekarstvi.cz/artkey/vnl-202204-0002_antifibrotic-therapy-and-its-indications-for-interstitial-pulmonary-fibrosis.php |
| Doi | http://dx.doi.org/10.36290/vnl.2022.045 |
| Klíčová slova | idiopathic pulmonary fibrosis; nintedanib; pirfenidon; progressive fibrosing interstitial lung diseases |
| Popis | Idiopathic pulmonary fibrosis and chronic fibrotic interstitial lung disease with progressive phenotype are characterized by fibrotic lung parenchyma. Current antifibrotic treatment does not affect pre-existing lung parenchyma fibrosis, but prevents fibrosis progression and reduces mortality by reducing fibrotization. This work summarizes fibrotic lung processes and their treatment options. © 2022, SOLEN s.r.o.. All rights reserved. |